S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

CVS Health (NYSE:CVS) Price Target Raised to $105.00 at Mizuho

Wednesday, November 10, 2021 | MarketBeat

CVS Health (NYSE:CVS) had its price target hoisted by equities research analysts at Mizuho from $98.00 to $105.00 in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage presently has a "buy" rating on the pharmacy operator's stock. Mizuho's target price would indicate a potential upside of 13.20% from the stock's current price.

Several other research analysts have also issued reports on CVS. Citigroup raised their price target on shares of CVS Health from $98.00 to $111.00 and gave the stock a "buy" rating in a report on Thursday, November 4th. They noted that the move was a valuation call. Raymond James raised their price target on shares of CVS Health from $95.00 to $115.00 and gave the stock a "strong-buy" rating in a report on Thursday, November 4th. Royal Bank of Canada raised their price objective on shares of CVS Health from $97.00 to $107.00 and gave the stock an "outperform" rating in a research report on Thursday, November 4th. Morgan Stanley raised their price objective on shares of CVS Health from $99.00 to $114.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 31st. Finally, Credit Suisse Group raised their price objective on shares of CVS Health from $100.00 to $107.00 and gave the stock an "outperform" rating in a research report on Friday, November 5th. Four analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $102.63.

Shares of NYSE CVS opened at $92.76 on Wednesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 0.94 and a quick ratio of 0.67. CVS Health has a 1 year low of $65.18 and a 1 year high of $96.57. The company has a 50 day simple moving average of $86.57 and a 200 day simple moving average of $84.68. The firm has a market cap of $122.45 billion, a PE ratio of 16.22, a price-to-earnings-growth ratio of 1.74 and a beta of 0.81.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, November 3rd. The pharmacy operator reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.18. CVS Health had a net margin of 2.66% and a return on equity of 14.16%. The firm had revenue of $73.79 billion during the quarter, compared to analyst estimates of $70.52 billion. During the same quarter last year, the business earned $1.66 EPS. The company's revenue was up 10.0% compared to the same quarter last year. As a group, research analysts anticipate that CVS Health will post 7.99 earnings per share for the current fiscal year.

In other news, COO Jonathan C. Roberts sold 108,870 shares of CVS Health stock in a transaction on Wednesday, November 3rd. The stock was sold at an average price of $95.00, for a total transaction of $10,342,650.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Troyen A. Brennan sold 82,757 shares of CVS Health stock in a transaction on Tuesday, October 26th. The stock was sold at an average price of $88.00, for a total value of $7,282,616.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 222,411 shares of company stock worth $20,387,951. Company insiders own 0.69% of the company's stock.

A number of institutional investors have recently made changes to their positions in CVS. Penserra Capital Management LLC bought a new stake in CVS Health in the 2nd quarter valued at about $25,000. MV Capital Management Inc. grew its holdings in CVS Health by 96.1% during the 2nd quarter. MV Capital Management Inc. now owns 400 shares of the pharmacy operator's stock valued at $33,000 after buying an additional 196 shares in the last quarter. D Orazio & Associates Inc. purchased a new position in CVS Health during the 2nd quarter valued at about $36,000. Smith Asset Management Group LP purchased a new position in CVS Health during the 2nd quarter valued at about $38,000. Finally, Albion Financial Group UT purchased a new position in CVS Health during the 2nd quarter valued at about $40,000. Institutional investors and hedge funds own 75.99% of the company's stock.

CVS Health Company Profile

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits, and Corporate/Other. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise.

Recommended Story: Range Trading

The Fly logo

Analyst Recommendations for CVS Health (NYSE:CVS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in CVS Health right now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.